Scarica l'app Stockscreener
135.83
2.26%
3.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Ligand Pharmaceuticals Inc Borsa (LGND) Ultime notizie
Ligand Pharmaceuticals Incorporated Stock Analysis and ForecastHigh-margin investment plays - PrintWeekIndia
What drives Ligand Pharmaceuticals Incorporated stock priceBreakout portfolio performance - Autocar Professional
Mark Your Calendar: Ligand Q2 2025 Earnings Report Coming August 7Key Details Inside - Stock Titan
What analysts say about Ligand Pharmaceuticals Incorporated stockExceptional trading performance - Autocar Professional
Is Ligand Pharmaceuticals Incorporated a good long term investmentHigh-velocity capital appreciation - jammulinksnews.com
Is Ligand Pharmaceuticals Incorporated stock a growth or value playFree Capital Allocation Plans - beatles.ru
Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND) and Sarepta Therapeutics (SRPT) - The Globe and Mail
Stifel reiterates Buy rating on Ligand Pharma stock at $143 price target - Investing.com Canada
Teacher Retirement System of Texas Has $534,000 Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals stock hits 52-week high at 130.0 USD - Investing.com Australia
Ligand Pharmaceuticals stock hits 52-week high at 130.0 USD By Investing.com - Investing.com Nigeria
What makes Ligand Pharmaceuticals Incorporated stock price move sharplyHigh Yield Opportunities - Newser
How Ligand Pharmaceuticals Incorporated stock performs during market volatilityFree Real-Time Trading Opportunities - Newser
Why Ligand Pharmaceuticals Incorporated stock attracts strong analyst attentionFree Access to Community - Newser
Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Announces Target Price $140 - 富途牛牛
Principal Financial Group Inc. Acquires 3,284 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Insider Sell Alert: John Kozarich Sells Shares of Ligand Pharmac - GuruFocus
Ligand Pharmaceuticals director Kozarich sells $116k in stock By Investing.com - Investing.com South Africa
Ligand Pharmaceuticals director Kozarich sells $116k in stock - Investing.com Australia
Ligand Pharmaceuticals Director John Kozarich Sells 934 Shares at $125/Share. - AInvest
Amalgamated Bank Has $564,000 Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand earns $5 million milestone as partner launches molluscum treatment By Investing.com - Investing.com South Africa
Ligand Pharmaceuticals (LGND) Soars 2.11% on ZELSUVMI Launch, Milestone Payment - AInvest
Pelthos Therapeutics shares rise 1.27% in after-hours after commercial launch of ZELSUVMI™ and merger with Channel Therapeutics. - AInvest
Pelthos, Ligand Gain After Launch Of First Prescription-At-Home Treatment For Water Warts - Stocktwits
ZELSUVMI's FDA Approval: A Breakthrough for Pelthos and a Windfall for Ligand? - AInvest
ZELSUVMI Launch Positions Ligand Pharmaceuticals for Growth in a Booming Skin Care Market - AInvest
Ligand earns $5 million milestone as partner launches molluscum treatment - Investing.com
Ligand Partner Pelthos Therapeutics Launches ZELSUVMI - MarketScreener
Ligand Pharmaceuticals Partner Pelthos Launches Molluscum Contagiosum Treatment Zelsuvmi - MarketScreener
Ligand (LGND) Advances with Successful Launch of ZELSUVMI Gel | - GuruFocus
Ligand Pharmaceuticals Partner Pelthos Therapeutics Launches ZELSUVMI™ for Molluscum Contagiosum Treatment - Quiver Quantitative
Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™ - GlobeNewswire
Breakthrough: First-Ever At-Home Treatment for Molluscum LaunchesLigand Secures $5M Milestone Payment - Stock Titan
GAMMA Investing LLC Has $62,000 Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Average Recommendation of “Buy” from Analysts - Defense World
Ligand’s LNHC concludes merger with CHRO - Yahoo Finance
Ligand Pharma Completes Merger Forming Pelthos Therapeutics - TipRanks
Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics - The Manila Times
Pelthos Therapeutics to Launch ZELSUVMI™ for Molluscum Contagiosum in July 2025 Following Merger with Ligand Pharmaceuticals - Quiver Quantitative
Ligand completes merger, Pelthos to launch molluscum treatment - Investing.com
0.97%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):